During infection or tumor growth, a type of specialized white blood cells called CD8+ T cells rapidly multiply within the spleen and lymph nodes and acquire the ability to kill diseased cells. Some of these killer T cells then migrate where required to vanquish the germs or cancers.
But how do killer T cells “learn” to leave their home base and amass within specific tissues like the skin, gut, and lung, or solid tumors? Finding the factors that cause T cells to function beyond the lymphoid system and in sites of infection or cancer has proven a tough challenge, but it’s essential for developing cancer-fighting immunotherapy strategies.
Writing in the journal Nature, researchers from The Scripps Research Institute and the University of California, San Diego report the discovery that a protein called “Runx3” programs killer T cells to establish residence in tumors and infection sites.
“Runx3 works on chromosomes inside killer T cells to program genes in way that enables the T cells to accumulate in a solid tumor,” said Matthew Pipkin, Ph.D., associate professor in the Department of Immunology and Microbiology on the Florida campus of The Scripps Research Institute.
The paper, “Runx3 programs CD8+ T cell residency in non-lymphoid tissues and tumors,” appears in Nature’s Dec. 14 issue.
There are two main strategies in cancer immunotherapy that employ killer T cells, Pipkin said. Checkpoint inhibitor blockade unleashes killer T cells, prompting them to accumulate in tumors more aggressively. Adoptive cell transfer, meanwhile, involves re-infusing a patient’s own immune cells after they have been engineered in the lab to recognize and destroy the patient’s specific cancer.
The adoptive cell transfer strategy has worked stunningly well in some blood cancers associated with the lymphoid system, so far. But there appears to be less efficient activity of T cells in solid tumors, Pipkin said.
“The gene programs and signals for how the T cells take up residence in tissues outside of the general circulation was not really well understood,” Pipkin said.
To discover factors that control T cell residency beyond the lymphoid system, Pipkin’s team worked collaboratively with the laboratory of UC San Diego’s Ananda Goldrath, who compared the gene expression of CD8+ T cells found in non-lymphoid tissue to those found in the general circulation. From a list of potential factors, they employed an RNA interference screening strategy which can test the actual function of thousands of factors simultaneously. Pipkin’s lab had developed the screening strategy in collaboration with Shane Crotty at the La Jolla Institute for Allergy and Immunology.
“We found a distinct pattern,” Pipkin said. “The screens showed that Runx3 is one at the top of a list of regulators essential for T cells to reside in nonlymphoid tissues.” Moreover, Runx3 was able to engage a specific gene program that is found in natural tissue-resident and tumor infiltrating CD8+ T cells, he said.
The group further assessed whether Runx3 had a role in directing white blood cells that attack solid tumors in mouse melanoma models. They found that adoptive cell transfer of cancer-specific killer T cells that overexpressed Runx3 delayed tumor growth and prolonged survival, while mouse models treated with those lacking Runx3 fared much worse than normal.
“If we enhance Runx3 activity in the cells, the tumors are significantly smaller and there is greater survival compared to the control group,” Pipkin said.
Knowing that modulating Runx3 activity in T cells influences their ability to reside in solid tumors opens new opportunities for improving cancer immunotherapy, Pipkin said.
“The upshot is we could probably use Runx3 to reprogram adoptively transferred cells to help drive them to amass in solid tumors,” he said. He added that a collaboration of specialists energized the research. “It was a fantastic collaboration, it all came together very quickly,” Pipkin said.
The Latest on: Cancer immunotherapy
- MIW815 plus spartalizumab safe, active among certain patients with advanced breast cancer, melanoma on June 17, 2019 at 1:09 pm
The most common primary diagnoses were melanoma (42.2%) and triple-negative breast cancer (13.3%). Most patients (72.3%) received prior immunotherapy. Patients received 400 mg IV spartalizumab (PDR001 ... […]
- γδ T cells: pleiotropic immune effectors with therapeutic potential in cancer on June 17, 2019 at 10:24 am
The potential of cancer immunotherapy relies on the mobilization of immune cells capable of producing antitumour cytokines and effectively killing tumour cells. These are major attributes of γδ T ... […]
- Checkpoint Challenge: When Releasing Immune Cell Brakes Is Not Enough to Stop Cancer on June 17, 2019 at 9:56 am
The 2018 Nobel Prize in Physiology or Medicine went to the scientific minds behind checkpoint blockade immunotherapy. The approach has produced striking results in some people with advanced cancer. It ... […]
- New Lung Cancer Advances: Nasal Swabs to Updates on CBD Use on June 17, 2019 at 7:13 am
Immunotherapy works by stimulating the native immune system to recognize cancer cells as foreign and killing them. Cancer cells have ways to fool the immune system into thinking that cancer cells ... […]
- Immunotherapy Drugs Market Worth $201.52 Billion by 2021 on June 17, 2019 at 6:00 am
According to a new market research report "Immunotherapy Drugs Market by Type of Drugs (Adult Vaccines, Checkpoint Inhibitors, Interferons Alpha), Therapy Area (Cancer, Autoimmune Diseases, Infectious ... […]
- World Cancer Immunotherapy Market Report 2019 - Outcome Potential / Fast Tracking / Funding / Technology Environment / Target Solutions on June 14, 2019 at 5:37 am
DUBLIN, June 14, 2019 /PRNewswire/ -- The "Cancer Immunotherapy Markets - Market Forecasts for Immuno-Oncology Therapeutics Including Executive and Consultant Guides and a Complete Listing of ... […]
- Immunotherapy drug shows potential to cure advanced lung cancer on June 13, 2019 at 6:25 am
In a new study including Yale Cancer Center and Smilow Cancer Hospital researchers, the cancer immunotherapy drug pembrolizumab (Keytruda), increased survival for patients with advanced non-small ... […]
- Cancer Immunotherapy Markets, 2023 - ResearchAndMarkets.com on June 10, 2019 at 5:36 am
The "Cancer Immunotherapy Markets - Market Forecasts for Immuno-Oncology Therapeutics Including Executive and Consultant Guides and a Complete Listing of Active Company Summaries 2019 to 2023" report ... […]
- As immunotherapy comes of age, cancer patients benefit from next-generation treatments on June 7, 2019 at 12:04 pm
I’ve seen many treatments come and go since I started working in gynecologic oncology 30 years ago. At that time, we treated all patients with advanced ovarian cancer the same way, as if their cancers ... […]
- Society for Immunotherapy of Cancer (SITC) Announces Recipients of 2019 Postdoctoral Cancer Immunotherapy Fellowship Awards on June 6, 2019 at 7:00 am
MILWAUKEE, Wis., June 6, 2019 /PRNewswire-PRWeb/ -- The Society for Immunotherapy of Cancer (SITC) is pleased to announce the recipients of three 2019 Fellowship Awards, which support the next ... […]
via Google News and Bing News